Prospectus Supplement to Prospectus dated May 6, 2021
Becton, Dickinson and Company
€400,000,000 0.000% Notes due 2023
€500,000,000 0.034% Notes due 2025
We are offering €400,000,000 aggregate principal amount of 0.000% Notes due 2023 (the “2023 notes”) and €500,000,000 aggregate principal amount of 0.034% Notes due 2025 (the “2025 notes” and, together with the 2023 notes, the “notes”). Interest on the 2023 notes will be payable in cash annually in arrears on August 13 of each year, beginning on August 13, 2022 and interest on the 2025 notes will be payable in cash annually in arrears on August 13 of each year, beginning on August 13, 2022. The 2023 notes will mature on August 13, 2023 and the 2025 notes will mature on August 13, 2025.
We may redeem the notes, at our option, in whole or in part at any time at the applicable redemption prices described in this prospectus supplement. See “Description of Notes—Optional Redemption.” In addition, we may redeem the notes in whole, but not in part, at any time in the event of certain developments affecting U.S. taxation. See “Description of Notes—Redemption for Tax Reasons.” If a change of control triggering event occurs as described in this prospectus supplement under the heading “Description of Notes—Offer to Repurchase Upon Change of Control Triggering Event,” we will be required to offer to purchase the notes from the holders.
Concurrently with this offering, Becton Dickinson Euro Finance S.à r.l, which is an indirect, wholly-owned finance subsidiary of the Company (“BD Finance”), is offering €900,000,000 aggregate principal amount of 0.334% Notes due 2028 and €900,000,000 aggregate principal amount of 1.336% Notes due 2041 (the “concurrent offering”). The notes offered in the concurrent offering will be fully and unconditionally guaranteed by us on a senior unsecured basis. The closing of this offering and the concurrent offering are not conditioned on each other. The concurrent offering is being made by means of a separate prospectus supplement and not by means of this prospectus supplement. This prospectus supplement is not an offer to sell or a solicitation of an offer to buy any securities being offered in the concurrent offering.
We expect to use the net proceeds from this offering, together with cash on hand and the net proceeds from the concurrent offering, to fund the purchase price and accrued and unpaid interest for the Tender Notes (as defined herein) validly tendered and accepted for purchase in the Tender Offers (as defined herein) and to redeem any Any and All Notes (as defined herein) that are not tendered in the Any and All Tender Offers (as defined herein), in accordance with the indenture governing the Any and All Notes. See “Recent Developments—Concurrent Tender Offers for Senior Notes” and “Use of Proceeds.” This offering is not contingent on the consummation of the Tender Offers. In the event that the Any and All Tender Offers or the Maximum Tender Offers (as defined herein) are not consummated, we intend to use the net proceeds from this offering for general corporate purposes, including the retirement of debt.
The notes will be our senior unsecured obligations and will rank equally in right of payment with all of our other senior unsecured indebtedness. The notes will be issued in minimum denominations of €100,000 and in integral multiples of €1,000 in excess thereof.
Each series of the notes constitutes a new issue of securities for which there is no established trading market. We intend to apply to list the notes on the New York Stock Exchange (“NYSE”). The listing application will be subject to approval by the NYSE. We expect trading in each series of the notes on the NYSE to begin within 30 days after the original issue date of the notes.
Investing in the notes involves risks that are described in the “Risk Factors” section of this prospectus supplement beginning on page S-
8 and in our Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q, which are incorporated by reference into this prospectus supplement (as such risk factors may be updated from time to time in our public filings).
Neither the Securities and Exchange Commission (the “SEC”) nor any other regulatory body has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the related prospectus. Any representation to the contrary is a criminal offense.
0.000% Notes due 2023
|
|
|
100.293% |
|
|
€401,172,000 |
|
|
0.200% |
|
|
€800,000
|
|
|
100.093% |
|
|
€400,372,000 |
0.034% Notes due 2025
|
|
|
100.000% |
|
|
€500,000,000 |
|
|
0.300% |
|
|
€1,500,000 |
|
|
99.700% |
|
|
€498,500,000 |
Total
|
|
|
|
|
|
€901,172,000 |
|
|
|
|
|
€2,300,000 |
|
|
|
|
|
€898,872,000 |
(1)
|
Plus accrued interest from August 13, 2021, if settlement occurs after that date. |
The underwriters expect to deliver the notes to purchasers in book-entry form through the facilities of Clearstream Banking S.A. (“Clearstream”), and Euroclear Bank SA/NV (“Euroclear”) against payment on or about August 13, 2021.
Joint Book-Running Managers
Barclays |
|
|
BNP PARIBAS |
|
|
Citigroup |
Goldman Sachs & Co. LLC |
|
|
J.P. Morgan |
|
|
Morgan Stanley |
MUFG |
|
|
Scotia Captital |
|
|
Wells Fargo Securities |
Co-Managers
Loop Capital Markets |
|
|
BNY Mellon Capital Markets, LLC |
|
|
ING |
|
|
IMI — Intesa Sanpaolo |
|
|
PNC Capital Markets LLC |
Siebert Williams Shank |
|
|
Standard Chartered Bank |
|
|
TD Securities |
|
|
US Bancorp |
The date of this prospectus supplement is August 10, 2021